For Immediate Release
Media Contact: Marilyn Gutierrez, Marketing Project Manager, 626.340.0452,
mgutierrez@stemcyte.com
StemCyte’s Global Leadership & Quality Standards Continue
StemCyte Taiwan Awarded FACT Accreditation
Covina, CA, October 25, 2012 – StemCyte, Inc. is proud to announce that StemCyte Taiwan has
met the eligibility requirements for accreditation by the Foundation for the Accreditation of
Cellular Therapy (FACT), an organization helping to assure the highest standards in cellular
therapy practices. StemCyte Taiwan’s accreditation achievement matches its continued FACT
accreditation at its Covina, California North American lab. The dual lab accreditation is further
evidence of StemCyte’s commitment to being an industry leader by maintaining the highest level
of quality controls across their global enterprise.
“Patients and families are at the forefront of our minds in everything we do at StemCyte. We
owe them our best and operating at the highest standard is an imperative,” said Ken Giacin,
StemCyte’s Chairman. “StemCyte Taiwan Cord Blood Bank takes great pride in receiving FACT
accreditation knowing it demonstrates our strong focus on excellence in all aspects of what we
do, patient care and lab practices alike,” said Charles Lu, President, StemCyte Taiwan.
FACT accredited organizations voluntarily comply with rigorous industry standards. They are
the only set of accreditation requirements addressing both clinical and laboratory practices.
“StemCyte is committed to producing and delivering cellular therapy products that consistently
meet the highest quality standards for safety, identity, purity and potency for patients in need,”
said StemCyte’s Global Medical Director, Dr. Wise Young, MD, PhD. “StemCyte Taiwan’s
accreditation to match our California lab’s ongoing accreditation demonstrates our global
commitment to delivering superior quality and consistency to the doctors, patients and parents we
serve.”
###
About StemCyte, Inc.
Located in the US, India and Taiwan, StemCyte has established one of the largest, most racially
diverse, and highest quality cord blood stem cell banks in the world. StemCyte has supplied over
1,750 cord blood products for over 70 life-threatening diseases to over 200 leading transplant
centers worldwide. StemCyte is actively involved in the development of new umbilical cord
blood-based cell therapies. The Company supports the largest clinical study for using unrelated
cord blood transplantation for thalassemia, one of the most common genetic diseases in the world,
and the development of trials investigating regenerative spinal cord therapies. StemCyte is one of
the only for-profit companies contracted by the US Department of HHS to help contribute clinical
grade cord blood units to the public National Cord Blood Inventory for unrelated transplants. Its
headquarters are in Covina, CA. To learn more visit www.StemCyte.com.
1589 W. Industrial Park Street, Covina, CA 91722 | 626.646.2500 | StemCyte.com